Literature DB >> 22357887

Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT.

Hamid Chalian1, Sandra M Tochetto, Hüseyin G Töre, Pedram Rezai, Vahid Yaghmai.   

Abstract

PURPOSE: To evaluate the reproducibility of liver tumor attenuation measurement performed by using the routinely used manual region-of-interest (ROI) method and that of measurement performed by using a semiautomated volumetric approach at computed tomography (CT).
MATERIALS AND METHODS: This HIPAA-compliant retrospective study had institutional review board approval. The requirement for patient informed consent was waived. Attenuation of colon cancer liver metastases in 208 patients was measured on portal venous phase multidetector CT images by using a single ROI, the average measurement in three ROIs on a single section, and with semiautomated segmentation of the entire tumor volume (volumetric attenuation) to evaluate intermethod agreement. Intraobserver and interobserver reproducibility were evaluated in the first 70 patients. Measurements were repeated after 30 days to assess intraobserver reproducibility. Differences between methods were tested by using repeated-measures analysis of variance. Intermethod, intraobserver, and interobserver agreements were tested by using Bland-Altman analysis and the Lin concordance correlation coefficient (ρc). P < .05 was considered to indicate a significant difference.
RESULTS: A total of 208 pathologically proven colon cancer hepatic metastases larger than 20 mm in diameter in 100 women and 108 men (mean age, 61.6 years ± 11.6 [standard deviation]; range, 28-87 years) were evaluated. Attenuation was significantly different between the three methods of measurement (P < .001 for all). Volumetric measurements had better intraobserver agreement (precision = 3.3%, ρc = 0.996, P < .001) than single-ROI measurements (precision = 12.0%, ρc = 0.947, P < .001) and measurements averaged over three ROIs (precision = 9.3%, ρc = 0.965, P < .001). Volumetric measurements also had better interobserver agreement (precision = 3.6%, ρc = 0.993, P < .001) than single-ROI measurements (precision = 11.3%, ρc = 0.957, P < .001) and the average measurement in three ROIs (precision = 8.5%, ρc = 0.976, P < .001).
CONCLUSION: Measurements of hepatic tumor attenuation at multidetector CT are reproducible. An approach based on the evaluation of whole-lesion attenuation demonstrated better reproducibility than ROI measurements. © RSNA, 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357887     DOI: 10.1148/radiol.11110106

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  12 in total

1.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

2.  Automated measurement of liver attenuation to identify moderate-to-severe hepatic steatosis from chest CT scans.

Authors:  Artit Jirapatnakul; Anthony P Reeves; Sara Lewis; Xiangmeng Chen; Teng Ma; Rowena Yip; Xing Chin; Shuang Liu; Ponni V Perumalswami; David F Yankelevitz; Michael Crane; Andrea D Branch; Claudia I Henschke
Journal:  Eur J Radiol       Date:  2019-10-25       Impact factor: 3.528

3.  Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.

Authors:  Les Roger Folio; Evrim B Turkbey; Seth M Steinberg; Andrea B Apolo
Journal:  Eur J Radiol       Date:  2015-06-10       Impact factor: 3.528

4.  Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.

Authors:  David Bonekamp; Susanne Bonekamp; Vivek Gowdra Halappa; Jean-Francois H Geschwind; John Eng; Celia Pamela Corona-Villalobos; Timothy M Pawlik; Ihab R Kamel
Journal:  Eur J Radiol       Date:  2013-12-03       Impact factor: 3.528

5.  Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study.

Authors:  Qin Li; Yongguang Liang; Qiao Huang; Min Zong; Benjamin Berman; Marios A Gavrielides; Lawrence H Schwartz; Binsheng Zhao; Nicholas Petrick
Journal:  Med Phys       Date:  2016-12       Impact factor: 4.071

6.  Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.

Authors:  Katharina S Winter; Felix O Hofmann; Kolja M Thierfelder; Julian W Holch; Nina Hesse; Alena B Baumann; Dominik P Modest; Sebastian Stintzing; Volker Heinemann; Jens Ricke; Wieland H Sommer; Melvin D'Anastasi
Journal:  Eur Radiol       Date:  2018-05-07       Impact factor: 5.315

7.  CT reconstruction algorithms affect histogram and texture analysis: evidence for liver parenchyma, focal solid liver lesions, and renal cysts.

Authors:  Su Joa Ahn; Jung Hoon Kim; Sang Min Lee; Sang Joon Park; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-11-19       Impact factor: 5.315

8.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

Authors:  Susanne Bonekamp; Zhen Li; Jean-François H Geschwind; Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Diane Reyes; Timothy M Pawlik; David Bonekamp; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

9.  Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.

Authors:  Waleed Shady; Vlasios S Sotirchos; Richard K Do; Neeta Pandit-Taskar; Jorge A Carrasquillo; Mithat Gonen; Constantinos T Sofocleous
Journal:  AJR Am J Roentgenol       Date:  2016-07-06       Impact factor: 3.959

10.  Differentiation between primary cerebral lymphoma and glioblastoma using the apparent diffusion coefficient: comparison of three different ROI methods.

Authors:  Sung Jun Ahn; Hyun Joo Shin; Jong-Hee Chang; Seung-Koo Lee
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.